Nano-X Imaging (NASDAQ:NNOX) Announces Earnings Results, Misses Estimates By $0.63 EPS

Nano-X Imaging (NASDAQ:NNOX) issued its quarterly earnings results on Wednesday. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.63), Zacks reports. Nano-X Imaging had a negative net margin of 926.05% and a negative return on equity of 116.93%. The business had revenue of $4.16 million during the quarter, compared to analysts’ expectations of $5.38 million.

Here are the key takeaways from Nano-X Imaging’s conference call:

• Commercialization expanded with Nanox.ARC installations at RadNet, an orthopedic IDN, urgent care, and the first Nanox Imaging Network site in Philadelphia; the company reported some sites completing hundreds of scans monthly and 10 U.S. distribution partnerships.
• The Nanox Imaging Network has begun receiving insurer payments of approximately $200–$700 per claim, while management estimates potential annual revenue of roughly $500,000 to $1 million per site depending on utilization and reimbursement. A new CMS code for AI analysis of coronary and aortic valve calcification may also support Nanox.AI adoption.
• Q2 revenue increased 37% year over year to $4.2 million, driven largely by the acquired Nanox Health IT business and continued growth in teleradiology, which averaged 14% year-over-year growth in the first half of 2026.
• Financial losses and liquidity pressures remain significant: adjusted EBITDA loss widened to $11.3 million, cash and restricted deposits fell to $31.4 million from $60 million at year-end, and the company recorded a $40.7 million non-cash impairment charge. Nanox subsequently raised $8.5 million through equity offerings and said it expects to continue seeking additional capital.
• Management acknowledged that commercialization has taken longer than expected and announced workforce and manufacturing reductions, including a 15% cut among Israeli employees and a two-thirds reduction in Korea, where chip production was idled. The company expects about $2 million in annualized savings beginning in 2027, while shifting production to third-party suppliers and preparing to sell its Korean facility.

Nano-X Imaging Stock Performance

Shares of NASDAQ:NNOX opened at $0.72 on Friday. The company’s fifty day moving average is $0.96 and its two-hundred day moving average is $1.66. Nano-X Imaging has a 1-year low of $0.67 and a 1-year high of $4.71. The stock has a market capitalization of $56.88 million, a price-to-earnings ratio of -0.34 and a beta of 1.26.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on NNOX. Zacks Research raised Nano-X Imaging from a “strong sell” rating to a “hold” rating in a research report on Monday, June 22nd. Cantor Fitzgerald reissued an “overweight” rating and set a $5.00 price target on shares of Nano-X Imaging in a research report on Monday, August 17th. Alliance Global Partners lowered shares of Nano-X Imaging from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $5.00 to $3.00 in a research note on Tuesday, July 7th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nano-X Imaging in a report on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Nano-X Imaging currently has a consensus rating of “Moderate Buy” and a consensus price target of $4.33.

Insider Activity

In other Nano-X Imaging news, Director Dan S. Suesskind acquired 50,000 shares of the stock in a transaction that occurred on Monday, July 27th. The stock was acquired at an average price of $0.93 per share, with a total value of $46,500.00. Following the transaction, the director directly owned 50,000 shares in the company, valued at approximately $46,500. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Erez Meltzer acquired 36,000 shares of the company’s stock in a transaction that occurred on Monday, July 27th. The shares were acquired at an average price of $0.93 per share, for a total transaction of $33,480.00. Following the purchase, the chief executive officer owned 36,000 shares of the company’s stock, valued at $33,480. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 95,443 shares of company stock valued at $89,706 over the last ninety days. Company insiders own 7.74% of the company’s stock.

Institutional Trading of Nano-X Imaging

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Aristides Capital LLC bought a new stake in shares of Nano-X Imaging in the 4th quarter worth approximately $30,000. CIBC Bancorp USA Inc. acquired a new stake in Nano-X Imaging in the third quarter worth $40,000. BNP Paribas Financial Markets increased its position in Nano-X Imaging by 193.7% in the second quarter. BNP Paribas Financial Markets now owns 11,994 shares of the company’s stock worth $62,000 after buying an additional 7,910 shares during the period. Russell Investments Group Ltd. increased its position in Nano-X Imaging by 62.1% in the third quarter. Russell Investments Group Ltd. now owns 13,787 shares of the company’s stock worth $51,000 after buying an additional 5,283 shares during the period. Finally, Tower Research Capital LLC TRC lifted its stake in Nano-X Imaging by 529.9% in the second quarter. Tower Research Capital LLC TRC now owns 13,794 shares of the company’s stock valued at $71,000 after buying an additional 11,604 shares during the last quarter. 21.49% of the stock is currently owned by institutional investors and hedge funds.

About Nano-X Imaging

Nano-X Imaging Ltd. is a medical technology company developing and commercializing a digital X-ray imaging platform designed to lower the cost and increase the accessibility of diagnostic imaging. Its flagship product, the Nanox.ARC, leverages a proprietary micro-electromechanical system (MEMS) based digital X-ray source and advanced image processing software to provide 2D and 3D imaging capabilities on a compact footprint. The system aims to streamline radiology workflows and facilitate point-of-care diagnostics in hospitals, clinics and outpatient settings.

The Nanox.ARC platform integrates a novel cold cathode X-ray source, which enables multiple emission points without the need for rotating anode tubes.